Abstract
GABAA receptors are the major inhibitory receptors in the CNS, and the target for benzodiazepines, barbiturates, and various other CNS depressants. Such drugs, however, lack selectivity for different GABAA receptor subtypes and thus, the pharmacological treatments of anxiety, epilepsy, insomnia, and mood disorders are accompanied by serious side effects. Consequently, the search for selective modulators with new scaffolds is still an urgent task.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
